-
Product Insights
NewComplement Factor D – Drugs In Development, 2024
The Complement Factor D pipeline drugs market research report outlays comprehensive information on the Complement Factor D targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Central Nervous System, Genito Urinary System, Ophthalmology, and Hematological Disorders which include indications of Alzheimer's Disease, Glomerulonephritis, Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease), Geographic Atrophy, Age Related Macular Degeneration, and Paroxysmal...
-
Product Insights
NewVascular Endothelial Growth Factor D – Drugs In Development, 2024
The Vascular Endothelial Growth Factor D pipeline drugs market research report outlays comprehensive information on the Vascular Endothelial Growth Factor D targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, Ophthalmology, and Cardiovascular which include indications of Solid Tumor, Oncology, Diabetic Macular Edema, Wet (Neovascular / Exudative) Macular Degeneration, and Refractory Angina. It also reviews key players...
-
Product Insights
NewNKG2 D Type II Integral Membrane Protein – Drugs In Development, 2024
The NKG2 D Type II Integral Membrane Protein pipeline drugs market research report outlays comprehensive information on the NKG2 D Type II Integral Membrane Protein targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology which include indications of Solid Tumor, and Non-Small Cell Lung Cancer. It also reviews key players involved in NKG2 D Type II Integral...
-
Product Insights
NewFAD-Dependent Decaprenylphosphoryl-Beta-D-Ribofuranose 2-Oxidase – Drugs In Development, 2024
The FAD-Dependent Decaprenylphosphoryl-Beta-D-Ribofuranose 2-Oxidase pipeline drugs market research report outlays comprehensive information on the FAD-Dependent Decaprenylphosphoryl-Beta-D-Ribofuranose 2-Oxidase targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Infectious Disease which include indications of Tuberculosis, and Pulmonary Tuberculosis. It also reviews key players involved in FAD-Dependent Decaprenylphosphoryl-Beta-D-Ribofuranose 2-Oxidase targeted therapeutics development with respective active and dormant or discontinued projects. Note:...
-
Innovation Ranking
Innovation Ranking – D-Link Corporation
D-Link Corp (DLC) is a communications and internet company in Taiwan. It designs, manufactures, and markets home surveillance, home networking, home automation, wireless, switching, surveillance, and network security products. It also offers accessories such as USB hubs; and network infrastructure solutions such as copper and fiber solutions. DLC provides its consumer, business solutions, and service provider solutions to digital home consumers, small office professionals, small-to-medium-sized businesses, and enterprise environments. It also offers various service provider solutions including home network solutions,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – D-121 in Leishmaniasis (Kala-Azar)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - D-121 in Leishmaniasis (Kala-Azar) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. D-121 in Leishmaniasis (Kala-Azar) Drug Details: D-121 (Oleylphosphocholine) is under development...
-
Product Insights
Innovations in 25-OH Vitamin D Tests – Global Pipeline Summary
GlobalData's Medical Devices sector report, "Innovations in 25-OH Vitamin D Tests - Global Pipeline Summary" provides comprehensive information about the 25-OH Vitamin D Tests pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress. The 25-OH Vitamin D Tests report provides key information and data related to: Extensive coverage of the 25-OH Vitamin D Tests under development Review details of major pipeline products which include product description, licensing and collaboration...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lonafarnib in Hepatitis D
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lonafarnib in Hepatitis D report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lonafarnib in Hepatitis D Drug Details: Lonafarnib (Zokinvy) is a synthetic tricyclic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ropeginterferon Alfa-2B LA in Hepatitis D
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ropeginterferon Alfa-2B LA in Hepatitis D report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ropeginterferon Alfa-2B LA in Hepatitis D Drug Details: Ropeginterferon...
-
Product Insights
NewHepatitis D – Drugs In Development, 2024
Empower your strategies with our Hepatitis D – Drugs In Development, 2024 report and make more profitable business decisions. Hepatitis D, also known as the delta virus, is an infection that causes the liver to swell. It is caused by the hepatitis D virus (HDV). Symptoms include yellowing of skin and eyes, joint pain, abdominal pains, vomiting, loss of appetite, and fatigue. Risk factors include receiving many blood transfusions, abusing intravenous (IV) or injection drugs, and being infected while pregnant. The...